TY - JOUR
T1 - Novel strategies in cancer therapeutics
T2 - Targeting enzymes involved in cell cycle regulation and cellular proliferation
AU - Liu, M. C.
AU - Marshall, J. L.
AU - Pestell, R. G.
PY - 2004/8
Y1 - 2004/8
N2 - Tumor development, growth, and progression depend on some combination of altered cell cycle regulation, excessive growth factor pathway activation, and decreased apoptosis. Understanding the complex molecular mechanisms that underlie these processes should therefore lead to the identification of potential targets for therapeutic intervention. The estrogen receptor and HER-2/neu were among the earliest targets investigated, ultimately leading to the widespread use of tamoxifen and trastuzumab, respectively, in the treatment of breast cancer. Major research advances have since led to other classes of targeted therapies, including cyclin-dependent kinase inhibitors, histone deactylase inhibitors, and receptor tyrosine kinase inhibitors. The following review provides a discussion of the molecular biology associated with each of these types of therapies as well as a detailed summary of the preclinical and clinical data published on selected compounds from each of these subgroups.
AB - Tumor development, growth, and progression depend on some combination of altered cell cycle regulation, excessive growth factor pathway activation, and decreased apoptosis. Understanding the complex molecular mechanisms that underlie these processes should therefore lead to the identification of potential targets for therapeutic intervention. The estrogen receptor and HER-2/neu were among the earliest targets investigated, ultimately leading to the widespread use of tamoxifen and trastuzumab, respectively, in the treatment of breast cancer. Major research advances have since led to other classes of targeted therapies, including cyclin-dependent kinase inhibitors, histone deactylase inhibitors, and receptor tyrosine kinase inhibitors. The following review provides a discussion of the molecular biology associated with each of these types of therapies as well as a detailed summary of the preclinical and clinical data published on selected compounds from each of these subgroups.
UR - http://www.scopus.com/inward/record.url?scp=4143074669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4143074669&partnerID=8YFLogxK
U2 - 10.2174/1568009043332907
DO - 10.2174/1568009043332907
M3 - Review article
C2 - 15320717
AN - SCOPUS:4143074669
SN - 1568-0096
VL - 4
SP - 403
EP - 424
JO - Current Cancer Drug Targets
JF - Current Cancer Drug Targets
IS - 5
ER -